Literature DB >> 17902023

Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?

Amanda B Cooper1, Jianmin Wu, Debao Lu, Mary A Maluccio.   

Abstract

INTRODUCTION: Hepatitis C is the most significant risk factor for development of hepatocellular carcinoma. Inflammation, fibrosis, and liver cell proliferation may contribute to cancer development either through malignant hepatocyte transformation or extracellular matrix remodeling within the tumor microenvironment. The study objective was to investigate differences in gene expression between patients with Hepatitis C (+/- cancer) and normal that might explain the increased cancer risk.
METHODS: Liver tissue was collected from three patient groups: 1) healthy patients, 2) Hepatitis C patients without cancer, 3) patients with Hepatitis C and hepatocellular carcinoma. Microarray analysis was performed on samples from each group. Western blot and real-time polymerase chain reaction (PCR) analyses corroborated the microarray data. A p value of 0.05 was set as significant.
RESULTS: Microarray analysis showed overexpression of autotaxin in patients with cancer versus hepatitis patients or normal patients. Rho GTPase binding proteins (Cdc42s) associated with lysophosphatidic acid signaling were also overexpressed in cancer patients. Real-time polymerase chain reaction showed overexpression of several factors associated with autotaxin in patients with Hepatitis C (+/- cancer) versus normal patients.
CONCLUSIONS: Patients with Hepatitis C and hepatocellular carcinoma show differential expression of various components of the autotaxin pathway versus normal patients. This merits further investigation in the context of early diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17902023     DOI: 10.1007/s11605-007-0322-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  14 in total

Review 1.  Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family.

Authors:  James W Goding; Bert Grobben; Herman Slegers
Journal:  Biochim Biophys Acta       Date:  2003-05-20

2.  Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma.

Authors:  Koji Fukui; Shinji Tamura; Akira Wada; Yoshihiro Kamada; Yoshiyuki Sawai; Kazuho Imanaka; Takahiko Kudara; Iichiro Shimomura; Norio Hayashi
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-30       Impact factor: 4.553

3.  Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells.

Authors:  S W Nam; T Clair; C K Campo; H Y Lee; L A Liotta; M L Stracke
Journal:  Oncogene       Date:  2000-01-13       Impact factor: 9.867

Review 4.  Bioactive lysophospholipids and their G protein-coupled receptors.

Authors:  W H Moolenaar
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

5.  Expression of autotaxin mRNA in human hepatocellular carcinoma.

Authors:  G Zhang; Z Zhao; S Xu; L Ni; X Wang
Journal:  Chin Med J (Engl)       Date:  1999-04       Impact factor: 2.628

6.  Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer.

Authors:  Hiroharu Yamashita; Joji Kitayama; Dai Shida; Makoto Ishikawa; Kotaro Hama; Junken Aoki; Hiroyuki Arai; Hirokazu Nagawa
Journal:  J Surg Oncol       Date:  2006-01-01       Impact factor: 3.454

7.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Authors:  Y Xu; Z Shen; D W Wiper; M Wu; R E Morton; P Elson; A W Kennedy; J Belinson; M Markman; G Casey
Journal:  JAMA       Date:  1998-08-26       Impact factor: 56.272

Review 8.  The ins and outs of lysophosphatidic acid signaling.

Authors:  Wouter H Moolenaar; Laurens A van Meeteren; Ben N G Giepmans
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

9.  Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.

Authors:  M L Stracke; H C Krutzsch; E J Unsworth; A Arestad; V Cioce; E Schiffmann; L A Liotta
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

10.  Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.

Authors:  Kotaro Hama; Junken Aoki; Masahiro Fukaya; Yasuhiro Kishi; Teruyuki Sakai; Rika Suzuki; Hideo Ohta; Takao Yamori; Masahiko Watanabe; Jerold Chun; Hiroyuki Arai
Journal:  J Biol Chem       Date:  2004-01-26       Impact factor: 5.157

View more
  24 in total

1.  CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients.

Authors:  Leilei Chen; Tim Hon Man Chan; Yun-Fei Yuan; Liang Hu; Jun Huang; Stephanie Ma; Jian Wang; Sui-Sui Dong; Kwan Ho Tang; Dan Xie; Yan Li; Xin-Yuan Guan
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 2.  Cutting-edge issues in primary biliary cirrhosis.

Authors:  Marco Folci; Francesca Meda; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 3.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

4.  Intrahepatic expression of genes related to metabotropic receptors in chronic hepatitis.

Authors:  Andrzej Cieśla; Maciej Kuśmider; Agata Faron-Górecka; Marta Dziedzicka-Wasylewska; Monika Bociąga-Jasik; Danuta Owczarek; Irena Ciećko-Michalska; Dorota Cibor; Tomasz Mach
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

5.  Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis.

Authors:  Qi Xia; An-mei Deng; Shan-shan Wu; Min Zheng
Journal:  Acta Pharmacol Sin       Date:  2011-07-18       Impact factor: 6.150

6.  Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.

Authors:  Malgorzata M Ptaszynska; Michael L Pendrak; Mary L Stracke; David D Roberts
Journal:  Mol Cancer Res       Date:  2010-03-02       Impact factor: 5.852

7.  Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.

Authors:  Jian-Min Wu; Yan Xu; Nicholas J Skill; Hongmiao Sheng; Zhenwen Zhao; Menggang Yu; Romil Saxena; Mary A Maluccio
Journal:  Mol Cancer       Date:  2010-03-31       Impact factor: 27.401

8.  Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections.

Authors:  Daniela M Schlatzer; Julia M Sugalski; Yanwen Chen; Jill Barnholtz-Sloan; Perica Davitkov; Fred E Hazlett; Nicholas Funderburg; Benigno Rodriguez; Michael M Lederman; Scott F Sieg; Mark R Chance; Donald D Anthony
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

Review 9.  Autotaxin.

Authors:  Jean A Boutin; Gilles Ferry
Journal:  Cell Mol Life Sci       Date:  2009-06-09       Impact factor: 9.261

10.  Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

Authors:  Shigeki Nakagawa; Lan Wei; Won Min Song; Takaaki Higashi; Sarani Ghoshal; Rosa S Kim; C Billie Bian; Suguru Yamada; Xiaochen Sun; Anu Venkatesh; Nicolas Goossens; Gretchen Bain; Gregory Y Lauwers; Anna P Koh; Mohamed El-Abtah; Noor B Ahmad; Hiroki Hoshida; Derek J Erstad; Ganesh Gunasekaran; Youngmin Lee; Ming-Lung Yu; Wan-Long Chuang; Chia-Yen Dai; Masahiro Kobayashi; Hiromitsu Kumada; Toru Beppu; Hideo Baba; Milind Mahajan; Venugopalan D Nair; Michael Lanuti; Augusto Villanueva; Angelo Sangiovanni; Massimo Iavarone; Massimo Colombo; Josep M Llovet; Aravind Subramanian; Andrew M Tager; Scott L Friedman; Thomas F Baumert; Myron E Schwarz; Raymond T Chung; Kenneth K Tanabe; Bin Zhang; Bryan C Fuchs; Yujin Hoshida
Journal:  Cancer Cell       Date:  2016-12-12       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.